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ABSTRACT
The transcription factor Sox2 is essential for
neural stem cells (NSC) maintenance in the
hippocampus and in vitro. The transcription factor
Emx2 is also critical for hippocampal development
and NSC self-renewal. Searching for ‘modifier’
genes affecting the Sox2 deficiency phenotype
in mouse, we observed that loss of one Emx2
allele substantially increased the telencephalic
b-geo (LacZ) expression of a transgene driven by
the 50 or 30 Sox2 enhancer. Reciprocally, Emx2
overexpression in NSC cultures inhibited the
activity of the same transgene. In vivo, loss of one
Emx2 allele increased Sox2 levels in the medial
telencephalic wall, including the hippocampal
primordium. In hypomorphic Sox2 mutants, retain-
ing a single ‘weak’ Sox2 allele, Emx2 deficiency
substantially rescued hippocampal radial glia
stem cells and neurogenesis, indicating that Emx2
functionally interacts with Sox2 at the stem cell
level. Electrophoresis mobility shift assays and
transfection indicated that Emx2 represses the
activities of both Sox2 enhancers. Emx2 bound to
overlapping Emx2/POU-binding sites, preventing
binding of the POU transcriptional activator Brn2.
Additionally, Emx2 directly interacted with Brn2
without binding to DNA. These data imply that
Emx2 may perform part of its functions by negatively
modulating Sox2 in specific brain areas, thus
controlling important aspects of NSC function in
development.
INTRODUCTION
The transcription factor Sox2, essential in pluripo-
tent stem cells of the blastocyst (1), is also highly
expressed in neural stem cells (NSC) and their early
progeny (2–6). Decreased expression of Sox2 in a mouse
hypomorphic Sox2 mutant causes important brain
and neurologic defects (3,7), which mimic signiﬁcant
aspects of the pathology of Sox2-deﬁcient patients
(8,9). In this hypomorphic mutant, we combined the
deletion of one Sox2 allele (Sox2b-geo knock-in) with the
deletion, on the other allele, of an upstream enhancer of
Sox2 (Sox2Enh), important for its expression in
telencephalic NSC (3,6,10–13). The hypomorphic
mutant, expressing Sox2 at a level about 30% that
of the wild-type, shows hippocampal stem cells loss,
corpus callosum interruption, parenchymal loss in
striatum and thalamus, decreased numbers of
GABAergic neurons and neurological defects, including
epilepsy (3,7). Recently (14), we showed that Sox2 em-
bryonic deletion leads to complete perinatal loss of
hippocampal stem cells. NSC from the forebrain of such
mutants become rapidly exhausted in in vitro neurosphere
culture.
The Emx2 transcription factor is expressed in the de-
veloping dorsal telencephalon, including prospective
hippocampus and cerebral cortex, from early embryogen-
esis (15,16). Its expression is maintained postnatally in
brain neurogenic regions, the subventricular zone (SVZ)
and hippocampus dentate gyrus (DG) (17,18).
Emx2 inactivation in mouse causes delayed
hippocampal development, with reduced cerebral cortex
and abnormal speciﬁcation of cortical areas (15,19–21).
In vitro, mutant Emx2/ NSC show increased prolifer-
ation in long-term neurosphere cultures (17).
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A common aspect of the defects in Sox2 and Emx2
mutants is the abnormal hippocampal development,
together with important NSC abnormalities in in vitro
long-term culture (see above, and 3,14,15,17,21). In this
work, we explored potential functional interactions
between Sox2 and Emx2 at the molecular level and,
in vivo, in mouse. We report that Emx2 negatively regu-
lates two Sox2 telencephalic-speciﬁc enhancers in vivo and
in transfection assays, by interfering with binding of
positive regulators to their cognate sites within the enhan-
cers. In vivo, Emx2 deﬁciency leads to some increase of
Sox2 in the medial wall of the telencephalon, and partially
counteracts hippocampal neurogenesis defects observed in
Sox2 deﬁcient (hypomorphic) mouse mutants.
MATERIALS AND METHODS
Mouse lines, X-gal staining and immunohistochemistry
The 50 and 30 enhancer- b-geo transgenic mice lines were
described in (6,11,22,23). The Sox2-hypomorphic (Sox2
Enh) and null (Sox2 b-geo) mutant alleles were as in (3).
The Emx2 null mutant mice (kindly provided by A.
Mallamaci) were described in (15).
X-gal staining, immunohistochemistry (IHC) and hist-
ology were as reported (6).
Glial ﬁbrillary acidic protein (GFAP)/nestin and BrdU
IHC on hippocampus and all histological analyses
were carried out as previously reported (3). IHC with
anti-Emx2 antibodies was as described (18). IHC with
anti-Brn2 antibody, a SantaCruz goat antibody (22) was
used (1:100).
Experimental procedures involving animals were
approved by the Italian Ministry of Health.
Transgenic neurosphere culture and lentiviral transduction
Neurosphere cultures were derived from E15.5 dorsal
telencephalon of transgenic brains as described (6,14),
expanded (in the presence of 400 mg/ml G418) and
transduced (in the absence of G418) with an internal
ribosome entry site-green ﬂuorescent protein (Emx2-
IRES-GFP) (or GFP-only control)-encoding lentivirus
at a multiplicity of infection of 5. To generate the
Emx2-transducing virus, the Emx2 coding sequence was
cloned, upstream to IRES-GFP, in place of the Sox2
coding sequence, in the lentiviral vector described in
refs. 7 and 14.
Two passages after transduction RNA was extracted,
reverse transcribed and analysed by real-time PCR
(MESA GREEN qPCR Master Mix Eurogentec) for the
expression of b-geo (lacZ), Emx2 and Sox2 with the follow-
ing primers: LacZ-f CTGGATCAAATCTGTCGATCC,
LacZ-r CGTATTCGCAAAGGATCAGC, Emx2-f GTC
CCAGCTTTTAAGGCTAGA, Emx2-r CTTTTGCCTT
TTGAATTTCGTTC, Sox2-f GGCAGCTACAGCATG
ATGCAGGAGC, Sox2-r CTGGTCATGGAGTTGTAC
TGCAGG; HPRT-f TCCTCCTCAGACCGCTTT,
HPRT-r CCTGGTTCATCATCGCTAATC; the dataset
are analysed with a 7500 System Software v1.4
(Applied Biosystem). Neurospheres cultured as above
from Emx2/ or wild-type embryonic brains were
expanded for one passage, total RNA was extracted and
analysed by real-time RT–PCR as above with the same
Sox2 and Emx2 primers. Expression levels normalized
versus HPRT expression.
Luciferase reporter constructs
The Sox2 50 telencephalic enhancer core region of 400 bp
was PCR ampliﬁed from the 0.4a-Sox2 promoter-b-geo
vector (22) using the following primers:
Fw: 50 CGAGGTACCGTCAAATAGGGCCCTTTT
CAG 30; Rv: 50 TATCTCGAGAAGCCAACTGACA
ATGTTGTGG 30 containing a KpnI and XhoI restric-
tion sites (underlined), for further cloning into the
pGL3-based plasmid containing a 215 bp minimal tk
promoter (a gift of Hitoshi Niwa) (50enh-tk-luc).
The reporter plasmid carrying mutations in the
ATTA-3 site (ATTA-3 site mut) was obtained as above,
starting from 0.4a-MUT Sox2 promoter-b-geo vector (22).
All other ATTA-site mut reporter constructs were simi-
larly obtained by PCR-based site-directed mutagenesis.
Primers for the ATTA-1/2 site mut plasmid:
Fw: 50CGAGGTACCGTCAAATAGGGCCCTTTT
CAGATTTTAAGGACAAAATAAAAGGAGTCTGC
TC30
Rv: 50TATCTCGAGAAGCCAACTGACAATGTT
GTGG 30 containing the desidered mutations (in
bold) and KpnI/XhoI restriction sites (underlined).
The ATTA-4 site mut plasmid was generated by
replacing a PstI cassette of the 50enh-tk-luc with a corres-
ponding cassette, containing the desiredmutation (in bold),
obtained after ampliﬁcation with the following primers:
Fw: 50 ACTCTGCAGGTCCCCTGCCGTTCGCCTTC
ATTTCCATAAGGAGAGGAGGAGAGGAGG 30
Rv: 50 CGGGTCGCTGCAGGGTCGCTCGGTGTTC
G 30
PstI restriction site (underlined) in both primers.
TheATTA-5/6 sitesmutplasmidwasgeneratedusing two
overlapping primers containing the desidered mutations (in
bold) to separately amplify the 50- and 30-portions of the
50 enhancer, in conjunction with external primers ﬂanking
the KpnI and XhoI sites of the 50enh-tk-luc vector. The full
mutated enhancer was obtained by reampliﬁcation of the
obtained fragments with the same external 50enh-tk-luc
primers. The sequences of the primers used are:
Fw1: 50 GCATCAACCTAGTAAGATGCTTGGCTAG
TTCTCGCTAAGGTCTGCAAC 30
Rv1 (XhoI-external primer): 50 TATCTCGAGAAGCCA
ACTGACAATGTTGTGG 30
Fw2 (KpnI-external primer): 50 CGAGGTACCGTCAA
ATAGGGCCCTTTTCAG 30
Rv2: 50 GTTGCAGACCTTAGCGAGAACTAGCCAA
GCATCTTACTAGGTTGATGC 30
The reporter plasmid carrying mutations in ﬁve
ATTA-sites was obtained by combining the mutations
via PCR.
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Figure 1. Emx2 deﬁciency increases activity of Sox2 telencephalic enhancers-driven lacZ transgenes. (A) X-gal stained E15.5 brains carrying b-geo
transgenes driven by the 50 Sox2 telencephalic enhancer (left) or by the 30 enhancer (right), of Emx2+/+, Emx2+/, or Emx2/ genotype, as indicated.
Dorsal (top row), ventral (middle row) and lateral (bottom row) views are shown. Increased X-gal staining is seen, most clearly in dorsal views, in
Emx2+/ as compared to Emx2+/+ brains, and in Emx2/ as compared to Emx2+/ brains. In the 50enhancer-transgenic brains, an X-gal-positive
spot on the ventral telencephalic vesicles, visibile in the ventral (arrow) and lateral views, has comparable intensity in Emx2+/+ and Emx2+/0 brains,
acting as an internal control for staining. Overall, 7/7 Emx2+/ transgenic embryos (50 construct, E15.5) showed increased lacZ expression relative to
Emx2+/+ from the same litter (4 embryos). Similarly, 7/8 Emx2+/ embryos carrying the 30 transgene showed increased lacZ activity relative to
Emx2+/+ controls (4 embryos). Homozygous Emx2/ 50 transgenic embryos were always (7/7) more intensely stained than their control heterozy-
gotes (Emx2+/) littermates (11 embryos); 7/7 of the Emx2/ 30 transgenics were more stained than their Emx2+/ heterozygous controls
(10 embryos). (B) X-gal stained brain coronal sections of 50 or 30 enhancer-lacZ transgenic forebrains of Emx2+/+ (top row), Emx2+/ (middle)
and Emx2/ (bottom) genotype. Arrow in B (30 enhancer) points to some dorsal expansion of X-gal staining signal in Emx2+/, as compared to
Emx2+/+ brain. (C) Relative RNA levels (real-time RT–PCR) of Emx2, b-geo (lacZ), and endogenous Sox2 in cultured NSC (neurospheres) from
Sox2 30 enhancer-b-geo transgenic brains, transduced with Emx2-GFP or GFP (control)—encoding lentiviruses, as indicated. RNA levels in control
(GFP-lenti-transduced) cells are set=1 (for non-normalized data, see Supplementary Figure S1). The values represent the mean±SD of n=2
independent RT–PCR experiments on each line performed in triplicate (all RNA levels—LacZ, Emx2, Sox2—signiﬁcantly differ between Lenti-Emx2
and Lenti-GFP transductions (P< 0.003 by Student’s t-test), except for endogenous Sox2 levels in line 2, which are comparable). (D) Relative RNA
levels (real-time RT–PCR) of endogenous Sox2 RNA in cultured NSC (neurospheres) from Emx2/ versus wild type embryonic brains. The values
represent the mean±SD of n=3 independent RT–PCR experiments on two wild-type and three Emx2-mutant independent cultures tested, each
performed in triplicate. (****P=6.3 e11 by Wilcoxon’s one-tailed test).
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For constructing the 3X POU/ATTA site 3 plasmid,
the combined POU/ATTA site (in bold type characters)
was multimerized to three copies, and subcloned into the
KpnI/XhoI site of the pGL3-tk luciferase vector, using the
following primers:
Fw: 50CACTGCTAATTAGCAATGCTAGGGTGCTAA
TTAGCAATGCTAGGGTGCTAATTAGCAATGCT
AGC 30
Rv: 50TCGAGCTAGCATTGCTAATTAGCACCCTAG
CATTGCTAATTAGCACCCTAGCATTGCTAAT
TAGCAGTGGTAC 30
For constructing the 2X ATTA site 1,2 plasmid, the
ATTA site 1,2 core sequence,
50 TTAATTACAAAATAAAATTAGTCTGCTCTTC
30, was dimerized (as a synthetic oligonucleotide) and
subcloned into the KpnI/XhoI site of the pGL3-tk
luciferase vector.
The Luciferase reporter vectors bearing BamHI/
SalI genomic DNA fragments of the 30enhancer were
described (11,23); their core sequence was essentially as
in (24): 50GGATCCCTAATTAATGCAGAGACTCTA
AAAGAATTTCCCGGGCTCGGGCAGCCATTGTGA
TGCATATAGGATTATTCACGTGGTAATGAGCACA
GTCGAC 30
These fragments were subcloned into the BamHI/SalI
site located 30 to the Luciferase gene.
The Nestin258-luciferase construct (a gift from H.
Kondoh) was previously described (25).
P19 transfection assays
For transfection experiments, P19 cells were grown in
MEM-ALPHA medium supplemented with PenStrep,
L-glutamine and 10% fetal bovine serum. 2 105/well
exponentially growing P19 cells were plated in
6-well-plates, and transfected the following day with
Lipofectamine 2000 (Invitrogen) according to supplier’s
instructions. Brieﬂy, medium in each well was replaced
with 1ml of Opti-MEM medium (Invitrogen) with 10 ml
of Lipofectamine 2000 (Invitrogen), with DNA. For
transfection experiments, we used 1 mg of the luciferase
reporter plasmid, and 500 ng of the Emx2 expression
vector (pCAGGS-Emx2, a gift from V. Broccoli) per well
if not otherwise indicated. In control experiments,
equimolar amounts of the Emx2 ‘empty’ vector
(pCAGGs) or the Otx2 expression vector (pCAGGS-
Otx2, a gift from V. Broccoli), were used. The pBluescript
vector was added to each transfection to equalize the total
amount of transfected DNA to 2 mg total in each reaction.
After 24 h, total cellular extracts were prepared and
Luciferase activity was measured according to the
Promega Luciferase reporter system protocol.
For cotransfection experiments with Brn2 and Emx2
expression vectors, Brn2 expression vector (a gift from
D. Mejiers) (or the ‘empty’ control) was transfected at
the ﬁxed amount of 500 ng/transfection or at increasing
amounts (+,++,+++: 125, 500, 1000 ng) where indicated;
in these experiments, Emx2 expression vector was added
(100 to 1000 ng) as indicated in the relevant Figures. The
‘empty’ vector was added to each transfection at the
proper concentration to equalize the total amount of
DNA transfected in each reaction to 2 mg. Sox2 expression
vector (activating the Nestin258-luciferase construct in
conjunction with Brn2, ref. 25) was added at the ﬁxed
amount of 500 ng/transfection.
In vitro protein expression and puriﬁcation
Emx2 (in pSG5), Brn2, GATA1 and GATA2 (in
pBluescript) were produced using in vitro transcription—
translation reticulocyte lysate system (TNT, Promega), ac-
cording to the manufacturer’s indication, in a total volume
of 50 ml for 1.5 h at 30C, using 2 mg plasmid template with
25 ml of reticulocyte lysate, and then frozen at 80C.
The amounts in ml of the TNT reactions used in
different experiments are indicated in Figure legends. To
use equivalent amounts of in vitro-synthethized proteins
(Brn2, Emx2, GATA1 or GATA2), TNT reactions were
performed in the presence of 35S methionine, the amounts
of protein produced were estimated by autoradiography
of western blot, normalized for the numbers of
methionines in each protein, and equivalent amounts of
each recombinant protein were used.
The Emx2 (or CP2 control, ref. 26) cDNAs were cloned
in frame into the pGEX2T vector. The Escherichia coli
BL21 strain cells were transformed with the above
plasmid and cultures were grown at midlogarithmic
phase (0.6 A600). Protein expression was induced with
0.1mM isopropyl-b-D-thiogalactopyranoside (IPTG) for
3 h at 37C. The GST-EMX2 protein present in the
soluble fraction was bound to GST-Sepharose 4B
(Amersham Bioscience) and puriﬁed according to the
manufacturer’s instructions.
Protein was eluted from sepharose, quantitated by
Coomassie blue staining in comparison to BSA standards,
and 1 mg of total protein (for GST-Emx2, GST-CP2 and
GST-only resins) was used for GST-pulldown of 35S
Brn2-containing TNT reaction as in (26,27).
Electrophoretic mobility shift assay and Chromatin
Immunoprecipitation
Electrophoretic mobility shift assay (EMSA) was per-
formed (28,29) by preincubating TNT-produced proteins
or nuclear extract (from the hippocampal stem cell line
AHP or from neurosphere cultures) for 30min on ice in
20 ml of binding buffer (75mM NaCl, 20% Ficoll, 10mM
Tris–HCl, pH 7.5, 0.5mM EDTA, 10mM DTT, 1 mg of
poly(dI-dC), together with 2 ml (5 104 cpm) of
32P-end-labelled oligonucleotide probes. The incubation
mixture was resolved by electrophoresis on a 5 or 6%
polyacrylamide gel (29:1, acrylamide/bisacrylamide ratio)
in 50mM Tris borate, 1mM EDTA, pH 8.2 (0.5XTBE)
buffer run at 4C at 150V for 3 h. Gel were dried and
exposed to a Kodak X-AR ﬁlm at 80C. For ‘supershift’
reactions, 1 ml of the 1:10 diluted mouse a-Emx2 antibody
(mouse ascites, kindly provided by F. Mavilio) or 8 ml of
the goat a-Brn2 antibody (undiluted) (Santa Cruz
Biotechnology) were added to the complete binding
reaction just prior to the addition of the labelled probe.
The following double-stranded oligonucleotides were
used as probes for EMSA (only the top strand is shown)
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(underlined sequences correspond to mutated
nucleotides):
ATTA-site 3: 50-TCGTCAAACTCTGCTAATTAGCAA
TGCTGAGAAA-30;
ATTA-site 3 mut1: 50-TCGTCAAACTCTGC
ATCCTTGCAGAGCTGAGAAA-30;
ATTA-site 3 mut2: 50-TCGTCAAACTCTGCTACGGCG
CAATGCTGAGAAA-30;
30-Enh: 50-GGCAGGTTCCCCTCTAATTAATGCAGA
GACTC-30;
ATTA-1/2 sites:
50-GGGCCCTTTTCAGATTTTAATTACAAAATAAA
ATTAGTCTGCTCTTCCTCGG-30;
ATTA-1/2 sites mut:
50-GGGCCCTTTTCAGATTTTAAGGACAAAATAA
AAGGAGTCTGCTCTTCCTCGG-30;
Delta1-Enh: 50-AGAGAGCAGGTGCTGTCTGCATT
ACCATACAGCTGAGCGC-30;
Nestin-Enh: 50-GTGTGGACAAAAGGCAATAATT
AGCATGAGAATCGGCCTC-30.
Chromatin immunoprecipitation (ChIP) was as de-
scribed (13).
RESULTS
Emx2 negatively regulates transgenic Sox2-b-geo
reporters
We initially bred mice carrying transgenic b-geo reporters
driven by Sox2 regulatory elements to Emx2 mutant
(Emx2+/) mice. The Sox2-b-geo transgene (6) is driven
by 5.7 kb of the Sox2 promoter/enhancer, and its neural
expression is progressively conﬁned to the telencephalon,
after E11.5. The SRR2 transgene (11,23) is driven by the
tk-promoter linked to an enhancer normally located im-
mediately 30 to the Sox2 coding region (these mouse lines
are denominated 50 and 30 enhancer lines, respectively; al-
ternative names in the literature for the 50 and 30 enhancers
include SRR1 and N2, and SRR2, respectively, 11,24,30).
Breeding with Emx2-mutant mice, we obtained E15.5
progeny consisting of embryos carrying the transgene in
the heterozygous state, together with the three possible
Emx2 genotypes (wild-type, +/+; heterozygote, +/;
homozygote, /).
For both constructs, loss of one Emx2 allele is
associated to signiﬁcantly increased b-geo expression
(evaluated by classical X-gal staining) (Figure 1A);
a further strong increase is observed in Emx2/ mice
(note, however, that the Emx2/ brain is abnormal, as
expected (15).
We conﬁrmed these results by X-gal staining of brain
sections (Figure 1B). The 50enhancer construct is
expressed in dorsal and medial areas of the telencephalic
ventricular zone and, to lower levels, ventrally, along the
ganglionic eminence, whereas the 30 enhancer construct is
more active in ventrolateral areas. In Emx2+/ heterozy-
gotes, the respective domains of expression were more
intensely stained, both anteriorly and posteriorly; add-
itionally, the extension of the X-gal-positive region was
somewhat increased towards the midline, in mice
carrying the 30enhancer construct (arrows). As expected,
homozygous Emx2/ mutants showed increased b-geo
expression, although matching the different areas is prob-
lematic due to morphological abnormalities. We conclude
from these Emx2 loss-of-expression experiments that
Emx2 negatively modulates two different telencephalic en-
hancers of Sox2 in the developing mouse brain.
We further asked whether abnormally increased levels
of Emx2 could inhibit Sox2 telencephalic enhancers in
neural cells. To this end, we derived independent NSC
cultures from the dorsal telencephalon of two E15.5
mice carrying the 30enhancer-b-geo construct, and we
transduced them with an Emx2-GFP-expressing lentivirus
(or with control GFP-expressing virus). In both cell popu-
lations, the b-geo reporter expression was strongly in-
hibited by the Emx2-expressing virus, as compared to
the control virus (Figure 1C). In one of the two lines,
which expressed moderate levels of Sox2, also the
endogenous Sox2 level was signiﬁcantly decreased; in the
second line, which showed a much higher expression of
endogenous Sox2, no signiﬁcant inhibition could be
observed (Figure 1C and Supplementary Figure S1); it is
possible that the ‘isolated’ enhancer guiding b-geo more
readily responds to acute, exogenous variations of Emx2
levels than the ‘full’ Sox2 locus, which is controlled by
various different regulatory regions. Taken together, the
above results indicate that Emx2 negatively regulates,
in vivo and in ex vivo derived neural progenitors, the
activities of Sox2’ telencephalic enhancers.
We also wished to address whether Emx2 deﬁciency
would affect endogenous Sox2 levels in NSC cultures, as
it does in vivo in the developing brain. To this end, we
measured endogenous Sox2 mRNA levels in NSC
cultures derived from Emx2-mutant telencephalon,
as compared to wild-type littermates cultures, by
real-time RT–PCR (Figure 1D). Emx2 ablation led to a
signiﬁcant (average 50%) increase in endogenous Sox2
levels in three independent mutant cultures tested
(Figure 1D and Supplementary Figure S2), conﬁrming
that expression levels of the resident Sox2 gene are
modulated by Emx2 in cultured neural stem/progenitor
cells.
Loss of a single Emx2 allele signiﬁcantly rescues
the hippocampal NSC deﬁciency of hypomorphic Sox2
mutant mice
To begin to address whether the Emx2-dependent inhib-
ition of Sox2 telencephalic regulatory elements has any
in vivo effects on Sox2-dependent brain phenotypes, we
selected for further studies the hippocampus neural
stem/progenitor cells of the hypomorphic Sox2b-geo/Enh
mutant (3,7), that expresses Sox2 (from the single residual
knock-down allele) at low levels (30% relative to normal,
whereas heterozygotes express 65%) (3,7). In these mice,
postnatal neurogenesis is strongly diminished, particularly
in the hippocampus. In particular, the number of
nestin/GFAP double-positive radial glia cells (a stem/
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progenitor cell expressing Sox2 (3,5) is drastically
decreased (3).
In Sox2 hypomorphic mutants, heterozygosis for a
mutated Emx2 allele was sufﬁcient to substantially
rescue the number of GFAP/nestin stem/progenitor cells
from about 20% to 60% of wild-type levels (Figure 2A
and B); additionally, the radial glia was converted
from a thin, poorly-developed appearance typical of
cells of the hypomorphic mutant, to quasi-normal
morphology (Figure 2A). In agreement, BrdU incorpor-
ation (Figure 2B) was increased to about 45% of wild-type
levels in Sox2b-geo/Enh; Emx2+/, versus about 30% in
Sox2b-geo/Enh; Emx2+/+ controls (even if loss of a single
Emx2 allele, per se, causes some decrease of BrdU incorp-
oration (Figure 2B, ref. 31, see section ‘Discussion’).
To interpret this result, we examined Sox2 expression in
wild-type mice in the prospective hippocampal area during
development. In this area, Sox2 and Emx2 are coexpressed
in a large proportion of cells (Figure 2C). At E 15.5, both
the medial and lateral walls of the telencephalon expressed
Sox2; however the medial wall of the lateral ventricle,
from which the hippocampus will originate, expressed
Sox2 at comparatively lower levels than the lateral wall
in the wild-type (Figure 2C, ﬁlled versus empty
arrowheads). On the other hand, the Emx2 level was
higher in the medial as compared to the lateral wall
(Figure 2C, arrowheads see also 15,20), pointing to an
inverse relation between Sox2 and Emx2 expression.
Within the medial telencephalic wall (prospective hippo-
campus region), an inverse Sox2/Emx2 relation is also
seen with an Emx2-high, Sox2-low region developing
adjacent to a comparatively Emx2-low, Sox2-high region
(Figure 2C, thin arrowheads; Supplementary Figure S3).
In Emx2+/ heterozygotes we noted a signiﬁ-
cant upregulation of Sox2 expression in the medial tele-
ncephalic, relative to the lateral wall, when compared to
wild-type mice (Figure 2C, arrowheads). This inverse cor-
relation suggests that, within the area from which the
hippocampus will arise, Emx2 may negatively modulate
Sox2 levels. This result is consistent with the possibility
that the loss of a single Emx2 allele in Sox2 hypomorphic /
Emx2+/ double mutants contributes, by upregulating the
deﬁcient Sox2 expression, to the observed radial glia
rescue.
Emx2 transfection in Sox2-positive P19 teratocarcinoma
cells inhibits the activity of reporter genes driven by the 50
or 30 Sox2 enhancer
The previous in vivo results, indicating that Emx2
somehow negatively modulates the Sox2 enhancers, raise
the question whether Emx2 effects on Sox2 are direct or
mediated by other factors. The 50- and 30-enhancers ‘core’
elements were previously deﬁned in vivo by transgenic
assays and, in vitro, by transfection in Embryonic Stem
(ES) Cells (11,22,23). Both elements contain POU sites,
known to be functionally important in ES and brain
cells, which bind speciﬁc transcription factors (Oct4 in
ES, Brn1 and Brn2 in neural cells) (11,22,23). In trans-
genic mice, 400 nt of the 50 enhancer recapitulate full
expression, but as little as 120 nt are sufﬁcient for some
speciﬁc activity (22). The 400 nt enhancer contains, in
addition to the two POU sites, several ATTA sites
(referred to as ATTA-1 to ATTA-6, Figure 3A), which
represent the core of potential homeobox transcription
factor-binding motifs (22), including Emx2. The more 50
POU site is combined with ATTA-3 site within a single
overlapping sequence. The 30 enhancer similarly contains
several ATTA sites, together with a previously
characterized POU-binding element (23) (Figure 3A).
To address the possibility that Emx2 directly affects
Sox2 enhancer function, and to investigate its molecular
mechanisms of action, we developed a simpliﬁed in vitro
transfection system. We performed transfection experi-
ments in P19 teratocarcinoma cells, using the 50 and 30
enhancer ‘core’ regions linked to a luciferase reporter.
P19 cells express Sox2 at high levels, but are negative for
both Emx2 and the putative neural Sox2 activators Brn1
and Brn2 (11,22), although they express the related POU
factor Oct3/4, an activator of Sox2 in ES cells (22,23); this
allows us to test for the effects of adding these exogenous
factors in appropriate combinations and dosage, and to
evaluate the effects on enhancer functions of different,
speciﬁc point mutations within transcription factors rec-
ognition sites.
We ﬁrst transfected into P19 cells a luciferase reporter
gene, driven by the minimal tk promoter linked to the core
50Sox2 enhancer, in the absence or presence of an
Emx2-expression vector.
Emx2 cotransfection strongly repressed the activity of
the enhancer, to a level just above that of the con-
trol enhancer-less tk-luciferase vector (Figure 3B).
Cotransfection with a vector expressing Otx2, a related
homeobox gene, or with empty vector gave no signiﬁcant
repression. Similarly, Emx2 repressed the activity of the
30Sox2 telencephalic enhancer (11,23), when assayed with
both a full size and a ‘core’ enhancer (22) construct
(Figure 3C), though the observed repression was less
pronounced than that observed with the 50 enhancer.
The repression caused by Emx2 was dose-dependent for
both the 50 and 30 enhancers (Figure 3D).
To identify the site where Emx2 binds to repress tran-
scription, we mutated, in different combinations, each of
six sites characterized by the ATTA sequence in the 50en-
hancer. Unexpectedly, all the mutations strongly
decreased the activity (in the absence of cotransfected
Emx2) (Figure 3E); the simultaneous mutation of
ﬁve out of six sites (1/2/4/5/6, leaving only ATTA-3),
essentially abolished the activity of the core enhancer
(Figure 3E). In these experiments, Emx2 cotransfection
further reduced the residual activity of the mutants to
the background level corresponding to the activity of the
tk-promoter-luciferase construct.
These experiments suggest that the mutation
of the ATTA sites destroys the binding of some (yet un-
identiﬁed) activator protein. In contrast, as the repressive
Emx2 activity is not abolished by any of the
mutations, Emx2 either binds to other unidentiﬁed sites,
or somehow antagonizes the activator at each of the
deﬁned sites.
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Emx2 binds a composite POU/Emx2 binding-site
(ATTA-3), and inhibits the binding of Brn2 to
the same site
We characterized by EMSA the binding of recombinant
Emx2 to all of the ATTA sites in the core 50 enhancer.
ATTA-3 resembles (Figure 4A) one of the few
characterized Emx2-binding sites, that of the Wnt1 gene
(32,33); furthermore, a similar site is located in the 30
enhancer (ATTA-4) just upstream to the already studied
(11,23), functionally important, POU site. In EMSA,
Figure 2. Emx2 deﬁciency (Emx2+/) rescues GFAP/nestin stem cells impairment in the hippocampus of Sox2-deﬁcient (Sox2b-geo/Enh) mutant
mice. (A) GFAP/nestin double immunoﬂuorescence of hippocampus DG in the indicated genotypes. GFAP/nestin-positive cells, strongly depleted
in Sox2-hypomorphic (Sox2b-geo/Enh) mutants, recover to a signiﬁcant extent in Sox2b-geo/Enh; Emx2+/ double mutants (asterisks mark vessels,
showing non-speciﬁc ﬂuorescence). (B) GFAP/nestin-positive cells and BrdU-positive cells. Wild-type is set=100%. n=5 mice per genotype;
*P 0.002 by Student’s t-test. (C) Double immunoﬂuorescence with anti Emx2 (red) and anti Sox2 (green) antibodies on E15.5 telencephalic
sections (confocal microscopy), in wild-type (Emx2+/+, top) and Emx2+/ heterozygotes (two different representative mice per genotype, out
of n=5 mice analysed). The Sox2 (green) channel is also separately shown on the right panels. In Emx2+/ brains, compared to Emx2+/+
controls, a comparative increase in the intensity of Sox2 staining is seen in the medial telencephalic wall (ﬁlled arrowhead) (comprising
the hippocampal primordium region, arrows), as compared with the outer/lateral wall (empty arrowhead) within the same section. In the
lower medial telencephalic wall, in the region of the prospective hippocampus, a boundary can be appreciated between two regions showing
Sox2-high/Emx2 low (ﬁlled arrow) and comparatively Sox2-low/Emx2 high levels (non-ﬁlled arrow) (see also magniﬁcation and channel separation
in Supplementary Figure S3).
Nucleic Acids Research, 2012, Vol. 40, No. 14 6467
Figure 3. Emx2 represses the activity of the 50 and 30 Sox2 telencephalic enhancers in transfection assays. (A) 50 and 30 Sox2 telencephalic enhancers.
Numbered squares: ATTA sites, underlined and bold in the sequences below. Boxed bold sequences: POU sites (11,22,23) in 50 and 30 enhancers
(B and C). Cotransfection of 50 or 30 enhancer-driven (black bars, full enhancer; striped bars, ‘core’ enhancer) tk-luciferase vectors, or ‘empty’
tk-luciferase vector (white bars), with Emx2 or Otx2 expression vectors, or with ‘empty’ vector. The mean activity of the enhancer-driven constructs
(with no cotransfected expression vector) is set=100% luciferase activity. (D) Cotransfection of 50 and 30-enh. luciferase constructs with increasing
amounts of Emx2-expression vector. (E) Luciferase activity of 50 enhancer constructs carrying mutations in the indicated ATTA sites, and their
response to cotransfection of the Emx2 expression vector (500 ng). Values represent the mean±SD of n 3 independent transfection experiments,
with each transfection done in triplicate.
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recombinant Emx2 (Supplementary Figure S4, panel A)
bound to the Wnt-1 oligonucleotide (originally chara-
cterized only by foot-printing) generating a complex,
that was super shifted by an anti-Emx2 antibody
(Supplementary Figure S4, panel B). Similarly, ATTA-3
was efﬁciently bound by Emx2 (Figure 4B, lanes 3–4;
Figure 4C, lane 21); two different mutations of ATTA-3
abolished Emx2 binding (Figure 4C, lanes 11 and 16,
versus lane 21). Further, the ATTA-3/Emx2 binding
was efﬁciently competed by excess unlabelled Wnt-1 or
ATTA-3 oligonucleotides, with similar kinetics
(Supplementary Figure S4B). We conclude that ATTA-3
can be bound, in vitro, by Emx2.
An oligonucleotide including the combined ATTA/
POU site (ATTA-3) binds (21) the ES cell factor OCT4
and its brain homologues Brn1 and Brn2. As Emx2
Figure 4. Emx2 binds to ATTA sites within the Sox2 50 and 30 enhancers, and antagonizes binding of the activator Brn2. (A) ATTA sequences
binding Emx2 and/or Brn2. Lowermost line: Brn2/POU consensus based on TFBS cluster (http://hscl.cimr.cam.ac.uk/TFBScluster) and our data.
Letter size is proportional to nucleotide frequency. The spacer (n) is 2–3 nt in previously validated sites (34,35). For the interaction of a POU factor
with its binding site, and spacer length, see (27). Boxed sequences are homologies to the Brn2 consensus. Underlined sequences correspond to the
previously reported Emx2 binding sequence (footprint) in the Wnt1 enhancer (32,33), and to homologous sequences within the 50 and 30 Sox2
enhancers. (B) EMSA with an ATTA-3 site probe (50 enhancer) and recombinant Emx2 and Brn2 proteins (as indicated above the lanes). Anti-Emx2
antibody was added in lane 8. Asterisk: supershifted band. Amounts of TNT product used (see section ‘Materials and Methods’): Emx2:+=3 ml;
++=6 ml. Brn2:+=3 ml;++=6 ml. a-Emx2 antibody:+=1 ml (of a 1:10 dilution of ascites ﬂuid). (C) EMSA with wild-type (lanes 19–23) and two
different mutated (lanes 9–13; 14–18) ATTA-3 site probes (50 enhancer). Amounts of TNT product used: Emx2:+=6 ml; Brn2:+=1.5 ml. (D)
Addition of increasing amounts of Emx2 (lanes 5–7) to ATTA-3 site probe (50 enhancer) together with a ﬁxed amount of Brn2 (as in lane 4). An
Emx2 retarded band appears, while the Brn2 band progressively disappears. Amounts of TNT product used: Emx2:+=4 ml;++=8ml;+++=12 ml.
Brn2:+=1ml. (E) EMSA with a probe from the 30 enhancer ATTA-4 site, showing ability to bind Emx2 or Brn2. Addition of Emx2 together with
Brn2 (lane 5) antagonizes Brn2 binding. Asterisks indicate bands supershifted by antibodies (lanes 6 and 7). Amounts of TNT product used:
Emx2:+=5ml. Brn2:+=2 ml. a-Emx2 antibody:+=1 ml (of a 1:10 dilution of ascites ﬂuid). a-Brn2 antibody (Santa Cruz):+=8 ml.
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negatively modulates the activity of Sox2 telencephalic en-
hancers in brain (Figure 1), we asked if Emx2 binding to
the POU sites in brain cells might interfere with the
binding of Brn factors. Brn2 bound, as expected, the com-
posite POU/ATTA-site 3 (ATTA-3) of the 50enhancer,
that was shown to bind Emx2 (Figure 4B, lanes 5 and
6). When Brn2 and Emx2 were added together, no
ternary Emx2-Brn2-probe complex was detected, suggest-
ing that the binding was mutually exclusive. Addition of
anti-Emx2 antibody caused the loss of the Emx2 band and
its supershift, but did not affect the Brn2 band (Figure 4B,
lanes 7 and 8). Importantly, Brn2 binding was abolished
(Figure 4C, lanes 12 and 17 as compared to lane 22) by the
same mutations that caused loss of Emx2 binding.
Adding increasing amounts of Emx2, in the presence of
a ﬁxed amount of Brn2, proportionally increased Emx2
binding, whereas Brn2 binding was strongly decreased
(Figure 4D, lanes 5–7). The repression of Brn2 binding
was observed already at relatively low levels of added
Emx2 (and Emx2 binding), and under conditions of
a large excess of labelled oligonucleotide probe; this
suggests that the repression of Brn2 binding is not
simply the result of a direct competition on the same
DNA molecule, but rather entails other indirect mechan-
isms (see below).
In the 30enhancer, a motif (ATTA-4) similar to the
Emx2-binding ATTA-3 site is located just upstream to
an already studied (11,22), functionally important, POU
site. We performed EMSA experiments with Emx2 and
Brn2 using the 30 enhancer ATTA-4-site. Again,
ATTA-4 (Figure 4A) bound both Brn2 and Emx2
(Figure 4E), and addition of Emx2 greatly decreased the
binding of Brn2 (Figure 4E, lanes 4 and 5). Similarly, to
the 50 site, mutation of this site abolished the binding of
both Emx2 and Brn2 (data not shown).
Emx2 inhibits Brn2 binding to ATTA sites 1,2 without
directly binding to DNA
The ATTA motif is part of a large number of core
sequences of distinct transcription factor-binding motifs,
which are difﬁcult to identify purely on the basis of the
DNA sequence. As the POU/ATTA sequence (ATTA-3)
binds both Oct3/4 and Brn1/Brn2 (21), and other se-
quences containing an ATTA motif bind Brn1 and Brn2
(33,34; Figure 4A), we tested all ATTA sites in the 50
enhancer for binding to these factors. Brn2 bound
(Figure 5A) an oligonucleotide containing both sites 1
and 2 (ATTA-1/2), whereas Emx2 did not bind (the
weak band migrating slightly faster than Brn2 in lane 3,
arrowhead, is due to a protein contained in the TNT
extract used for Brn2 synthesis, see lane 2). We could
not detect any binding of Emx2 to the ATTA-1/2 probe
even when adding Emx2 in the absence of Brn2, in
amounts equal or greater than those able to generate a
strong shifted band with the ATTA-3 probe in a control
binding run in parallel (Supplementary Figure S5).
Mutation of the conserved TT doublet in the ATTA
motif abolished Brn2 binding, leaving only the fast
TNT-derived band (lanes 10 and 11). The Brn2 band
was almost completely ablated by addition of anti-Brn2
antibody (lane 4). Finally, excess unlabelled ATTA-1/2
oligonucleotide competed the binding of the previously
validated Brn2-binding site, ATTA-3 in the 50 enhancer
(22 and present article) as efﬁciently as unlabelled
ATTA-3 site oligonucleotide did (Figure 5B, lanes 4 and
5, versus lane 3). In contrast, a mutated ATTA-1/2 site
oligonucleotide failed to compete (lane 6). We conclude
that Brn2 can bind to the ATTA-1/2 site in a
sequence-speciﬁc way.
As shown in Figure 4D, Emx2 might inhibit the binding
of Brn2 to the POU/ATTA site (ATTA-3) oligonucleotide
both by direct DNA binding and by other indirect mech-
anisms. We tested the effects of Emx2 addition to the
ATTA-1/2 site oligonucleotide, in the presence of Brn2.
Emx2 addition (Figure 5A, lane 5) almost completely
abolished Brn2 binding, already at low Emx2 concentra-
tions. Similar or higher amounts of the haematopoietic
transcription factors GATA-1 and GATA-2 did not inter-
fere with Brn2 binding (Figure 5A, lanes 6 and 7), nor did
addition of a TNT lysate prepared by transcription/trans-
lation of an ‘empty’ vector in control experiments (data
not shown).
In additional experiments (Figure 5C) Emx2 prevented
Brn2 binding, in a dose-dependent fashion, to two inde-
pendently characterized Brn2-binding sites (Figure 4A),
those in the Delta and Nestin genes neural enhancers
(34,35).
ATTA-1/2 and ATTA 3 probes were also tested with
nuclear extracts from the neural (adult hippocampal)
AHP cell line (Figure 5D and E); endogenous Brn2
bound to both probes (Figure 5E, lanes 1 and 2;
Figure 5E, lane 1) generating bands that were supershifted
by anti-Brn2, but not anti-GATA-1 (Figure 5D, lanes 3
and 4); and were properly competed by the same un-
labelled oligonucleotide, but not by its mutated version
(Figure 5D, competitors: lane 5:ATTA-1/2; lanes 6 and
7: mutated ATTA-1/2; lane 8: ATTA-3). Also in this
neural cell context, the addition of increasing amounts
of Emx2 (but not of GATA-1) caused a sharp decrease
of Brn2 binding, already at low Emx2 concentrations
(Figure 5E, lanes 2–4, compare to lanes 1 and 5).
Overall, the experiments reported above (Figures 4
and 5) demonstrate that Emx2 prevents the binding of
transcription factors (in this case Brn2) to their cognate
motifs via mechanisms independent of its binding to
DNA; one possible mechanism might be protein–protein
interaction between Emx2 and Brn2. In a GST-pull down
assay, a GST–Emx2 fusion protein retained in vitro
synthesized Brn2 (Figure 5F), indicating that Emx2 and
Brn2 proteins are able to physically interact.
Emx2 functionally antagonizes Brn2
POU factors, including Oct4 and neural transcription
factors Brn1 and Brn2, were characterized as activators
of the Sox2 30 enhancer in co-transfection experiments,
and the mutation of the POU/ATTA site (ATTA-3 site)
in the 50enhancer (22) or of the POU site in the 30enhancer
(11,22) substantially decreased the activity of Sox2 trans-
genic constructs, suggesting that Brn1 and Brn2 factors
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Figure 5. Emx2 antagonizes the binding of Brn2 to ATTA-1/2 sites in the 50 enhancer, and to previously characterized Brn2 binding sites in other
neural enhancers. (A) EMSA with a probe containing ATTA sites 1 and 2 (50 enhancer); added recombinant proteins, and Brn2 antibody,
are indicated above the lanes. The probe binds recombinant Brn2 (arrow), but not Emx2 (TNT- arrowhead indicates a non-speciﬁc band seen
also with TNT extract only). Addition of Emx2 antagonizes Brn2 binding (lane 5). No antagonism is seen upon addition of GATA1 or GATA2
(lanes 6 and 7). Amounts of TNT product used (see section ‘Materials and Methods’): Brn2:+=1.5 ml; Emx2:+=4 ml; GATA1/2:+=4 ml. a-Brn2
antibody (Santa Cruz):+=8 ml. (B) EMSA with an ATTA-3 site probe (a previously validated Brn2 binding site in the 50 enhancer (11,22,23);
binding of Brn2 is efﬁciently competed by wild-type non-labelled ATTA-1/2 sites oligonucleotide (lane 5), but not by its mutated version (lane 6).
Competition is as efﬁcient as with the ‘self’ oligonucleotide (lane 4). Amounts of TNT product used: Brn2:+=1.5 ml. Competitor amounts: Self
(ATTA-3):+=25X (molar excess of cold competitor oligonucleotide); ATTA-1/2:+=25X; ATTA-1/2 mut:+=25X. (C) EMSA with probes
containing previously validated Brn2 binding sites in the nestin and Delta-1 enhancers. Brn2 binding (arrow) is antagonized by simultaneous
Emx2 addition in a dose-dependent way. Asterisk: Brn2 antibody-supershifted band. Amounts of TNT product used for Delta 1-enhancer :
Brn2:+=2ml; Emx2:+=1 ml;++=2 ml;+++=3 ml; ++++=4 ml. a-Brn2 antibody:+=8ml (Santa Cruz). Amounts of TNT product used for
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may be positive regulators of Sox2 transcription in the
brain (11,22,23).
To evaluate the respective roles of Brn2 and Emx2
in transfection experiments we linked to the minimal
tk-promoter the ATTA-1/2 or the POU/ATTA
(ATTA-3) site (the latter as a trimer) from the 50enhancer.
We transfected the construct into P19 teratocarcinoma
cells (which express Sox2) in the presence of different
amounts of Brn2-and/or Emx2 expression vectors
(Figure 6). In the absence of Emx2, Brn2 strongly
stimulated the activity of the ATTA-1/2 construct in a
dose-dependent way and, to a lesser extent, that of the
ATTA-3 construct (Figure 6A and C). The Brn2-
dependent stimulation of the ATTA-1/2 construct was
repressed to basal levels (just above the level of the
tk-luc reporter, lane 9 versus lanes 1 and 2), by
cotransfection of progressively increasing amounts of the
Emx2-expression vector (Figure 6B). Cotransfection of
Figure 5. Continued
Nestin-enhancer: Brn2:+=2 ml; Emx2:+=4ml. a-Brn2 antibody:+=8ml (Santa Cruz). (D) EMSA with ATTA-1/2 site probe and nuclear extracts
from AHP neural cells. Two complexes are generated (arrows) with both ATTA-3 (lane 1, ‘+’ as in ref. 21) and ATTA-1/2 (lane 2), which are
supershifted by anti-Brn2 (lane 3), but not anti-GATA1 antibodies (lane 4). Binding of Brn2 to ATTA-1/2 is efﬁciently competed by unlabelled
ATTA-3 (lane 8), by ‘self’ ATTA-1/2 (lane 5), but not by mutated ATTA-1/2 (lanes 6 and 7) oligonucletides. Unlabeled competitor oligonucleotides
were added in 25-fold molar excess (+) or 50-fold molar excess (++). (E) EMSA with ATTA-3 probe and nuclear extracts from AHP cells. Added
recombinant proteins (Emx2, GATA-1) are indicated above the lanes. The Brn2 retarded complex (lane 1, arrow) (see also ref. 21 and panel D) is
sharply decreased following addition of Emx2 (lanes 2–4), but not of control GATA-1 (lane 5). The lower, Emx2-containing complex is progressively
increased in parallel with the addition of Emx2. This complex has the same mobility of that generated by direct binding of recombinant Emx2 to the
ATTA-3 probe (lane 6). (F) Emx2 and Brn2 directly interact in a GST pulldown assay. Brn2 is retained by GST-Emx2, but not by GST-CP2 control
resin (which gives a weak signal equivalent to that seen with the ‘empty’ resin GST).
Figure 6. Emx2 represses Brn2-transactivated ATTA-1/2 and ATTA-3 sites—tk luciferase reporter constructs in a dose-dependent way. (A) Brn2
dose-dependent transactivation of ATTA-1/2 sites (50 enhancer) (Brn2:+,++,+++, 125, 500, 1000 ng) (B and C) Emx2 dose-dependent repression of
Brn2-dependent transactivation of ATTA-1/2 sites construct (B) and of ATTA site 3 construct (C) (Brn2:+, 500 ng; Emx2:+,++,+++,++++; 100,
200, 500, 1000 ng). In A, luciferase activity is expressed in arbitrary units, where 1 is the activity of the tk luc reporter; in B and C, 100% luciferase
activity is set to the maximum observed activity. The horizontal line in A and B represents the background activity of the ATTA-1/2 site construct in
the absence of cotransfected Brn2. (*P< 0.007 by Student’s t-test, non-parametric, Welch correction) (D) Nestin-enhancer (258wt)-driven luciferase
reporter, transactivated by cotransfected Sox2 expression vector 500 ng (as in 25), is cotransfected with increasing amounts of Emx2 expression
vector, in the presence (+Brn2) or absence (Brn2) of Brn2 expression vector (Brn2: 500 ng; Emx2: +, ++,+++; 125, 250, 500 ng). Brn2 addition
antagonizes the repressive effect of Emx2 (**P< 0.001; ***P< 0.0002 by Student’s t-test, non-parametric, Welch correction). 100% luciferase activity
is set to that observed without Emx2 cotransfection for both +Brn2 and Brn2 samples. In the absence of cotransfected Brn2, the activity of the
construct was about 20% lower (marginally signiﬁcant, data not shown) than in the presence of Brn2. Note that a Sox2-expression vector was
cotransfected in all the experiments, as Sox2 had been reported to increase the activity of the present reporter in other cell types (25). Values
represent the mean±SD of n 3 independent transfection experiments, with each transfection in triplicate.
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control ‘empty’ vector, instead of Emx2 expression
vector, yielded a slight inhibition only at the highest
tested levels, ensuring speciﬁcity of the Emx2 repression
observed (Figure 6B, lanes 10–13). Similarly, on the
ATTA-3 construct, Brn2-dependent stimulation was in-
hibited by Emx2 (Figure 6C), though the observed repres-
sion is weaker. Thus, Brn2 is an activator at both the
ATTA-3 [as previously shown in vivo and in vitro (22)]
and the ATTA-1/2 sites, and Emx2 inhibits the transcrip-
tional activity at the same sites, antagonizing Brn2-
dependent stimulation. As Emx2 does not bind to
ATTA-1/2 site sequences (Figure 5A), this inhibition
may be caused by mechanisms that do not strictly
require Emx2 binding to the DNA. The somewhat lower
effect of Emx2 in the Brn2-dependent system, as
compared to the drastic effect observed with the full
‘core’ element (in the absence of cotransfected Brn2)
(Figure 3), probably reﬂects the modest enhancer
activity of the individual ATTA sites in isolation, as
compared with the cooperative activity of the multiple
sites active in the full enhancer (Figure 3).
Is the Emx2 inhibitory effect limited to the Sox2 50 and
30 enhancers? To evaluate this point, we performed experi-
ments using the nestin enhancer, that is positively
regulated by transfection of Brn factors, in conjunction
with Sox2 (25). As shown above (Figure 5C), Emx2
addition antagonized Brn2 binding (in EMSA) to this
enhancer. In transfection experiments in P19 cells, in the
absence of transfected Brn2, Emx2 strongly inhibited the
activity of the enhancer already at low concentrations
(Figure 6D, ‘Brn2’, open squares). In this condition,
enhancer activity likely depends on the related POU
factor Oct3/4, expressed in P19 cells. In contrast, the add-
ition of Brn2 (‘+Brn2’, ﬁlled squares) completely pre-
vented the Emx2 repression at low/intermediate Emx2
levels, and substantially attenuated it at the highest
Emx2 level (Figure 6D). Note that, in P19 cells, the
addition of Brn2 per se stimulates the activity of the
enhancer only minimally (20%, data not shown),
indicating that the observed Brn2-dependent att-
enuation of Emx2-mediated repression is not the result
of independent stimulation of gene activity by Brn2;
rather, the excess Brn2 may directly ‘titrate’ Emx2
activity. These results, together with those reported
above, suggest that Emx2 and Brn2 antagonize each
other’s activities.
Emx2 binds to the 50enhancer in vivo
To ascertain if Emx2 interacts in brain cells with the Sox2
regulatory elements, we performed in vitro ChIP with
anti-Emx2 antibodies, using chromatin from embryonic
telencephalon (E14.5), from wild-type and Emx2-null
(negative control) embryos. A fragment comprising the
ATTA-3 and the adjacent ATTA-1/2 sites was bound by
Emx2 in wild-type chromatin, but not in Emx2-null chro-
matin (Figure 7). No binding was detected in an adjacent
region B, comprising ATTA-5 and 6 sites, and lying 30 to
the bound DNA region. We conclude that Emx2 likely
functionally interacts with the Sox2 regulatory region
in vivo.
DISCUSSION
Emx2 is a transcription factor involved in hippocampal
growth and in cortex patterning (19,36). With the excep-
tion of the Wnt1 and FGF8 genes (32,37,38), there are few
identiﬁed neural Emx2 targets. Here we show, by in vivo
and in vitro experiments, that Emx2 negatively regulates
two characterized Sox2 enhancers. Loss of a single Emx2
allele increases Sox2 expression in the E15.5 medial
telencephalic wall and partially rescues an hippocampal
phenotype dependent on Sox2 deﬁciency. Our results,
together with data of the literature, suggest that Emx2
may control aspects of Sox2 expression and brain devel-
opment by antagonizing the activities of transcriptional
activators, such as Brn2.
Emx2 negatively modulates Sox2 telencephalic enhancers
in vivo
Sox2 neural expression in chick (30) and mouse
(6,11,22,23,39) is regulated by multiple enhancers.
Among the best characterized mouse enhancers are the
50 and 30 Sox2 enhancers studied here, which direct trans-
genic reporter gene expression to the telencephalon, the 50
enhancer being more active in dorso-medial regions, and
the 30 enhancer in ventro-lateral regions. Emx2 is
expressed in the dorsal telencephalon in a posterior
medial to anterior lateral concentration gradient, that
intercepts the wide Sox2 expression domain; at the
cellular level, the two expression domains substantially
overlap within the ventricular zone, allowing for potential
cross-regulation (3,19,36). In our experiments (Figure 1),
the loss of one or both Emx2 copies substantially
Figure 7. Emx2 is bound to the Sox2 enhancer in vivo. ChIP with
anti-Emx2 antibodies of E14.5 embryonic brain chromatin from
wild-type and Emx2/ control embryos. Region A, containing
ATTA-3 site is immunoprecipitated from wild-type, but not
Emx2-null chromatin. The previously described Wnt1 enhancer con-
taining an Emx2 binding site (33) is used as a control (Wnt1), and is
similarly precipitated from wild-type, but not mutant, chromatin.
Antibodies used are indicated below the lanes. Input: input chromatin.
IgG: anti-IgG control antibodies. Emx2: anti-Emx2 antibodies.
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increases the expression of transgenes driven by the 50 or
the 30 Sox2 enhancers, indicating that the normal levels of
Emx2 may inhibit to some extent the activities of enhan-
cers of Sox2. The inhibitory activity of Emx2 is further
reﬂected in the decreased activity of the same enhancers
brought about by Emx2 overexpression in NSC cultures
(Figure 1C).
Does the altered regulation of Sox2 enhancers by Emx2
modify the levels of endogenous Sox2 in vivo? Overall, in
developing brain, Sox2 levels are not highly changed in
Emx2 +/ embryos, but signiﬁcant modulation can be
appreciated at speciﬁc locations. In the late embryo,
Sox2 and Emx2 are coexpressed in the prospective
hippocampal domain; at this stage, in the lateral ventricle,
regions of high Sox2 expression show relatively lower
Emx2, and regions of high Emx2 expression have lower
Sox2 levels (Figure 2C). This inverse correlation is particu-
larly evident in the medial telencephalic wall, where
the hippocampus primordia develop (Figure 2C and
Supplementary Figure S3). Loss of a single Emx2 allele
results, in this region, in increased Sox2 expression
(Figure 2C and Supplementary Figure S3). Thus, effects
of Emx2 deﬁciency on Sox2 may be more evident in
speciﬁc regions/developmental stages, possibly depending
on expression levels of Emx2 itself, or interactions with
other factors. This conclusion is in agreement with
the rather subtle phenotipic effects of changes in Emx2
levels observed in the cortex as compared to the hippo-
campus (36).
Heterozygous Emx2 deﬁciency antagonizes the
hippocampal NSC loss of Sox2 hypomorphic mutants
An important question arising from our present results, is
whether heterozygous Emx2-deﬁciency (that, by itself, has
little effect on brain development, 15,20,36) has any
phenotypic consequences on Sox2-dependent functions.
Both Emx2 homozygous mice and Sox2 mutants (Sox2
hypomorphic and Sox2 conditional-null mice) show severe
hippocampal defects, indicating that both genes are essen-
tial for hippocampal development (3,14,15). In the hippo-
campus, Sox2 is required for postnatal NSC survival;
complete Sox2 ablation by E12.5 results in the loss of
hippocampal neurogenesis and DG severe hypoplasia,
between P2 and P7 (14). Moreover, in adult Sox2
hypomorphic (Sox2b-geo/Enh) mutants, expressing 30%
of the normal Sox2 RNA, nestin/GFAP radial glia cells
(a Sox2-expressing neural stem/progenitor cell) (3,5,40) in
the hippocampus are importantly decreased (Figure 2).
As Sox2 and Emx2 are coexpressed in the hippocampal
primordium (Figure 2) and in the adult hippocampus (as
well as in the hippocampal AHP cell line (Supplementary
Figures S6 and S7), a reduction in Emx2 dosage may be
expected to affect Sox2-dependent functions in this region.
In adult hypomorphic Sox2 mutants, heterozygous
Emx2-deﬁciency strongly increases the number of nestin/
GFAP radial glia cells and, to a lesser extent, BrdU in-
corporation (Figure 2A and B); note that, in wild-type
mice, heterozygous Emx2 deﬁciency, per se, only slightly
raises the number of nestin/GFAP radial glia cells and
decreases, rather than increases, BrdU incorporation
(Figure 2A and B; ref. 31). These results demonstrate
that Emx2 deﬁciency rescues, in part, at least one well
characterized Sox2-dependent NSC phenotype. These
data, taken together with the increased Sox2 expression
in the medial lateral ventricle wall (that includes the pro-
spective hippocampus) of heterozygous Emx2-deﬁcient
mice (Figure 2C, Supplementary Figure S3), are thus con-
sistent with the hypothesis that Emx2 deﬁciency may con-
tribute to phenotypic rescue by raising Sox2 expression.
Of course, additional mechanisms might also contribute to
the observed phenotype.
Emx2 represses telencephalic enhancers in transfection
assays, directly binds to enhancer sequences in vitro and
antagonizes binding of POU transcriptional activators
To begin to address at the molecular level of our in vivo
data, we performed EMSA and transfection experiments
with P19 cells, that express Sox2, and can be manipulated
by transfection to express Brn2 and/or Emx2 (absent in
the basal state). We propose two mechanisms whereby
Emx2 might downregulate Sox2 enhancer activity
(Figures 4, 5 and 6; Supplementary Figure S8).
Firstly, Emx2, by directly binding to its cognate sites
in DNA, might prevent the activity of other transcrip-
tion factors which bind to sites overlapping the Emx2
motif; secondly, Emx2 might repress transcription by
antagonizing the binding to DNA of transcription
factors, without direct DNA binding, through protein–
protein interactions. As to the ﬁrst mechanism, Emx2
directly binds to 50 (ATTA-3) and 30enhancer (ATTA-4)
sites in the Sox2 gene (Figure 4), which are also bound
by the POU factors Brn1 and Brn2; importantly,
these factors were previously implicated in Sox2 activity
on the basis of in vivo experiments (transfection, trans-
genic mice and ChIP (11,22,23). As mutations at the
ATTA-3 site abolish the binding of both Emx2 and
Brn2, their binding sites are likely functionally
overlapping, and their binding might be mutually exclu-
sive; indeed, we did not detect by EMSA (even at high
protein concentrations, data not shown) any band of
mobility slower than that of Brn2, that might suggest
the formation of a ternary complex of DNA with
both factors. Moreover, in EMSA, the addition of
increasing amounts of Emx2 resulted in increased
binding of Emx2, together with progressive disappearance
of the Brn2 band (Figure 4).
The second mechanism is suggested by the following
observations: the binding of Brn2 to ATTA-sites in Sox2
enhancers and to other previously validated Brn2 sites
(nestin, delta; 22,34,35) is prevented by Emx2 addition,
in the absence of any binding of Emx2 itself to the
same sequences (Figure 5). Emx2 and Brn2 might be
reciprocally antagonistic (Figure 6) through direct
protein–protein interaction, which would prevent Brn2
binding to regulatory sequences, and transcriptional
activation (Figure 6). Indeed, GST pull-down experi-
ments show that Brn2 and Emx2 may physically interact
(Figure 5F). Our present interpretation is in agreement
with data reported by other authors in a different experi-
mental system; Sahara et al. (37) reported that Emx2
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represses SP8 trancription factor-dependent activity of the
FGF8 promoter without binding to the promoter itself;
moreover, other authors reported that Emx2 and SP8
physically interact (38).
TheDNAmotif recognized by Brn2 in our experiments is
a rather degenerate one, centred on an ATTA motif poten-
tially recognized by many transcription factors (41). It can
be hypothesized that, in addition to Brn2, other transcrip-
tion factors, particularly, among neural factors, the Brn1
homolog, or Oct6, might bind to this sequence, and could
thus be antagonized by Emx2. The 50 enhancer is also
bound by Oct3/4 at early developmental stages, and
Oct3/4 is required for its activity in ES cells (22) and in
the early neural plate (13), leading to the suggestion that
an exchange between early Oct3/4 and later Brn/Oct factors
binding is important in the early function of this element
(13,22). Of note, this enhancer is active in P19 cells, which
do not express neural POU factors, but do express Oct3/4;
Emx2 addition by cotransfection can antagonize both
basal 50 enhancer activity (presumably dependent on
Oct3/4 binding, 13,22), as well as Brn-stimulated activity
(Figures 3 and 6). This may, again, reﬂect a wider ability by
Emx2 to antagonize different POU factors, which may dif-
ferently act on Sox2 (and other genes) regulation at differ-
ent developmental stages and in different telencephalic
regions.
Additional data suggest that these mechanisms do oper-
ate in vivo. In fact, Emx2 binds to a fragment comprising
the 50 ATTA-3 site in nuclei from normal telencephalon, in
ChIP experiments (Figure 7). This fragment lies within a
120 bp DNA region that mediates POU site-dependent
reporter gene expression in the telencephalon of transgenic
embryos (22).
In conclusion, we propose that Emx2 contributes to the
modulation of Sox2 expression by antagonizing Brn2 and
possibly other activators able to bind the ATTA core
sequence. The mechanism may not be restricted to the
Sox2 enhancers, as at least the nestin enhancer may be
similarly regulated (Figures 5C and 6D). It provides a
wide scope for regulation, depending on the afﬁnities of
Emx2 for its DNA target and/or protein interactors, and
on the relative ratios between Emx2 and brain transcrip-
tion factors.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–8.
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